Can AstraZeneca plc’s Share Price Return To 3,625p?

Will AstraZeneca plc (LON: AZN) be able to return to its previous highs?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Right now I’m looking at some of the most popular companies in the FTSE 100 to try and establish whether or not they have the potential to return to historic highs.

Today I’m looking at AstraZeneca (LSE: AZN) (NYSE: AZN.US) to ascertain if its share price can return to 3,625p.

Initial catalyst

First of all, we need to establish what caused AstraZeneca to hit its all-time high of 3,625p per share during January of 2002. However, combing through AstraZeneca’s press releases, it appears that the only event announced by the company during this period was the approval of two cancer drugs.

Surprisingly, the approval-for-sale of Crestor, which became AstraZeneca’s bestselling product to date, came during November of 2002. I should also point out that AstraZeneca reached its all-time high of 3,625p per share at a time when the FTSE 100 as a whole was slumping, after the internet bubble burst during 1999.

But can AstraZeneca return to its former glory?

But can AstraZeneca’s share price return to 3,652p? Well, investors have been expressing concern for the past year or so about the company’s sliding sales following the company’s loss of exclusive manufacturing rights for its blockbuster Crestor treatment. Indeed, thanks to the loss of Crestor, City analysts are predicting that revenues will slump 10% this year followed by a 5% slump next year. 

However, AstraZeneca’s management has not been complacent and has been trying to build up the company’s treatment pipeline, in an attempt to fill the void left by Crestor. What’s more, there are rumours that AstraZeneca could be hunting for a big fish to acquire, which could complete change the company’s outlook.

That said, a recent report put out by analysts’ at market data company Morningstar, revealed that out of all the major international biotechnology companies, AstraZeneca had the least promising treatment pipeline. 

This AstraZeneca’s weak treatment pipeline does make me anxious. Nonetheless, investors are not placing a premium on AstraZeneca’s shares, which leads me to believe that many of the concerns over the company’s pipeline are already priced in. Indeed, AstraZeneca currently trades at a forward P/E of 11.4, compared to peer GlaxoSmithKline, which trades at a forward P/E of 14.2.

Foolish summary

Even though AstraZeneca’s new treatment pipeline lags that of its peers and the company’s sales are falling rapidly, market sentiment appears positive. In particular, AstraZeneca’s share price currently printed a 10-year high following rumours that the company was looking to acquire a US peer. This took the company’s share price within inches of 3,625p.

So overall based on AstraZeneca’s recent strength, I feel that the company’s share price can return to 3,625p. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

> Rupert does not own any share mentioned within this article. The Motley Fool has recommended shares in GlaxoSmithKline.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »